The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

PDLIM3  -  PDZ and LIM domain 3

Homo sapiens

Synonyms: ALP, Actinin-associated LIM protein, Alpha-actinin-2-associated LIM protein, PDZ and LIM domain protein 3
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PDLIM3


High impact information on PDLIM3

  • This result suggests the possibility that genetic variation at the LDL receptor locus or a closely linked locus on chromosome 19 may be responsible for metabolic alterations in ALP pattern B that account for a substantial proportion of the familial predisposition to coronary artery disease in the general population [2].
  • The maximum logarithm of odds (LOD) score of 4.07 was observed at a recombination fraction of 0.04, assuming 100% penetrance of ALP pattern B, and 4.27 at a recombination fraction of zero, assuming 90% penetrance of pattern B [2].
  • Results: ZOL maintained the mean level of total ALP at the middle of the reference range, whereas those treated with risedronate showed a linear increase in total ALP from the 6-month post-treatment time-point [6].
  • Here, we used mutagenesis, kinetic analysis, and computer modeling to identify the residues important for the binding of known ALP inhibitors to the TNALP active site [7].
  • MATERIALS AND METHODS: We measured biochemical markers of bone turnover (bone-specific alkaline phosphatase [bone ALP], intact N-terminal propeptide of type I collagen, and C-terminal crosslinked telopeptide of type 1 collagen) and BMD of the spine and hip at baseline and after 1 year of alendronate or placebo [4].

Chemical compound and disease context of PDLIM3


Biological context of PDLIM3

  • Although this strong SMF exposure did not affect cell proliferation, it up-regulated cell differentiation and matrix synthesis as determined by ALP and alizarin red stainings, respectively [13].
  • Our data demonstrate the efficacy of fish oil fatty acids in counteracting the proatherogenic lipid profile of the ALP but also that the apoE genotype influences responsiveness to this dietary treatment [5].
  • We conclude that the favorable influence of dietary n-3 PUFA on the ALP may be mediated, in part, through an increase in the plasma activity and gene expression of lipoprotein lipase in human adipose tissue [14].
  • Serum bone-specific alkaline phosphatase (S-bone ALP) and serum osteocalcin (S-OC) were assessed as markers of bone formation [15].
  • Lack of association between lipaemia and central adiposity in subjects with an atherogenic lipoprotein phenotype (ALP) [16].

Anatomical context of PDLIM3

  • Interestingly, this group included genes that encode actin filament binding and regulatory proteins, such as gelsolin, PDZ and LIM domain 3 (PDLIM3) and troponin I1 [17].
  • ALP activity was synergistically increased by the treatment with a specific MEK-1 inhibitor PD98059 and rhBMP-2 in both cell lines [18].
  • When administered at intermediate stages of osteoblast differentiation (days 12, 15 and 18) BSP remained refractory to rhOP-1 whereas the ALP was increased almost 2-fold, independent of the constitutive levels of mRNA expression [19].
  • Changes were comparable but more pronounced in the tibia group, and marker concentrations remained increased at the end of study (bone ALP, 86 vs 74 U/L; OC, 14.9 vs 7.7 mug/L; ICTP: 5.6 vs 3.3 mug/L at day 84 after osteosynthesis, P <0.05 in tibia; 80 vs 70 U/L, 8 vs 5.2 mug/L, and 3.5 vs 3.2 mug/L, respectively, in the malleolar fracture group) [20].
  • RESULTS: In intact articular cartilage, ALP accumulated to a significantly higher degree than myoglobin [21].

Associations of PDLIM3 with chemical compounds

  • A type I collagen synthesis inhibitor L-azetidine-2-carboxylic acid, as well as osteocalcin (OCN), significantly antagonized Smad3-stimulated ALP activity and mineralization of MC3T3-E1 cells [22].
  • However, in our PCOS patients, because of relatively low triglyceride levels, complete ALP is uncommon [23].
  • The change in ALP and bilirubin observed from the precholangiographic value up to 2 and 12 months afterward was not significantly different in those with and without DS [24].
  • The objective of this study was to determine whether a predominance of small, dense LDL (LDL-III, d = 1.044-1.063 g/ml) in the circulation in association with an atherogenic lipoprotein phenotype (ALP) (i.e. LDL-III > 100 mg/dl, an elevated plasma triglyceride and a low high density lipoprotein cholesterol) alters LDL reactivity towards APG [25].
  • Vitamin A is a potent inducer for liver/bone/kidney alkaline phosphatase (L/B/K ALP) in a variety of tissues [26].

Analytical, diagnostic and therapeutic context of PDLIM3

  • OBJECTIVE: To compare the efficacy of arthroscopic lavage plus administration of corticosteroids (ALC), arthroscopic lavage plus administration of placebo (ALP), and joint aspiration plus administration of corticosteroids (JAC) in knee arthritis, and to evaluate whether clinical or histologic characteristics determine outcome [3].
  • ALP scintigraphy may represent a functional assay for early, premorphological cartilage alterations in human arthritis as well [21].
  • In a randomized, double blind, placebo-controlled, cross-over study, 51 male subjects expressing an atherogenic lipoprotein phenotype (ALP) had their diets supplemented with fish oil for 6 weeks [14].
  • A dietary intervention study was undertaken to examine the effects of an ALA-enriched diet in 57 men expressing an atherogenic lipoprotein phenotype (ALP) [27].
  • The DNA analysis revealed that the cells of the control group and the HOP-26 positive cells showed a 5 times higher cell growth compared to the STRO-1 and ALP positive cells [28].


  1. Exclusion of muscle specific actinin-associated LIM protein (ALP) gene from 4q35 facioscapulohumeral muscular dystrophy (FSHD) candidate genes. Bouju, S., Piétu, G., Le Cunff, M., Cros, N., Malzac, P., Pellissier, J.F., Pons, F., Léger, J.J., Auffray, C., Dechesne, C.A. Neuromuscul. Disord. (1999) [Pubmed]
  2. Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Nishina, P.M., Johnson, J.P., Naggert, J.K., Krauss, R.M. Proc. Natl. Acad. Sci. U.S.A. (1992) [Pubmed]
  3. Comparison of efficacy of arthroscopic lavage plus administration of corticosteroids, arthroscopic lavage plus administration of placebo, and joint aspiration plus administration of corticosteroids in arthritis of the knee: A randomized controlled trial. van Oosterhout, M., Sont, J.K., Bajema, I.M., Breedveld, F.C., van Laar, J.M. Arthritis Rheum. (2006) [Pubmed]
  4. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Bauer, D.C., Black, D.M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., Thompson, D.E., Ewing, S.K., Delmas, P.D. J. Bone Miner. Res. (2004) [Pubmed]
  5. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Minihane, A.M., Khan, S., Leigh-Firbank, E.C., Talmud, P., Wright, J.W., Murphy, M.C., Griffin, B.A., Williams, C.M. Arterioscler. Thromb. Vasc. Biol. (2000) [Pubmed]
  6. Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate. Hosking, D., Lyles, K., Brown, J.P., Fraser, W.D., Miller, P., Diaz Curiel, M., Devogelaer, J.P., Hooper, M., Su, G., Zelenakas, K., Pak, J., Fashola, T., Saidi, Y., Fink Eriksen, E., Reid, I.R. J. Bone Miner. Res. (2007) [Pubmed]
  7. Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase. Kozlenkov, A., Le Du, M.H., Cuniasse, P., Ny, T., Hoylaerts, M.F., Millán, J.L. J. Bone Miner. Res. (2004) [Pubmed]
  8. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. Garnero, P., Stevens, R.E., Ayres, S.A., Phelps, K.V. Journal of clinical pharmacology. (2002) [Pubmed]
  9. How often are liver function tests normal in acute biliary pancreatitis? Dholakia, K., Pitchumoni, C.S., Agarwal, N. J. Clin. Gastroenterol. (2004) [Pubmed]
  10. A hepatoma-associated alkaline phosphatase, the Kasahara isozyme, compared with one of the isozymes of FL amnion cells. Higashino, K., Kudo, S., Otani, R., Yamamura, Y. Ann. N. Y. Acad. Sci. (1975) [Pubmed]
  11. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Okazaki, R., Miura, M., Toriumi, M., Taguchi, M., Hirota, Y., Fukumoto, S., Fujita, T., Tanaka, K., Takeuchi, A. Endocr. J. (1999) [Pubmed]
  12. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Van der Luit, A.H., Budde, M., Zerp, S., Caan, W., Klarenbeek, J.B., Verheij, M., Van Blitterswijk, W.J. Biochem. J. (2007) [Pubmed]
  13. Strong static magnetic field stimulates bone formation to a definite orientation in vitro and in vivo. Kotani, H., Kawaguchi, H., Shimoaka, T., Iwasaka, M., Ueno, S., Ozawa, H., Nakamura, K., Hoshi, K. J. Bone Miner. Res. (2002) [Pubmed]
  14. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. Khan, S., Minihane, A.M., Talmud, P.J., Wright, J.W., Murphy, M.C., Williams, C.M., Griffin, B.A. J. Lipid Res. (2002) [Pubmed]
  15. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Gerdhem, P., Isaksson, A., Akesson, K., Obrant, K.J. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. (2005) [Pubmed]
  16. Lack of association between lipaemia and central adiposity in subjects with an atherogenic lipoprotein phenotype (ALP). Minihane, A.M., Khan, S., Talmud, P.J., Williams, D.L., Wright, J.W., Murphy, M.C., Griffin, B.A., Williams, C.M. Int. J. Obes. Relat. Metab. Disord. (2000) [Pubmed]
  17. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Keira, Y., Noguchi, S., Kurokawa, R., Fujita, M., Minami, N., Hayashi, Y.K., Kato, T., Nishino, I. Neurosci. Res. (2007) [Pubmed]
  18. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. Higuchi, C., Myoui, A., Hashimoto, N., Kuriyama, K., Yoshioka, K., Yoshikawa, H., Itoh, K. J. Bone Miner. Res. (2002) [Pubmed]
  19. Effects of osteogenic protein-1 (OP-1, BMP-7) on bone matrix protein expression by fetal rat calvarial cells are differentiation stage specific. Li, I.W., Cheifetz, S., McCulloch, C.A., Sampath, K.T., Sodek, J. J. Cell. Physiol. (1996) [Pubmed]
  20. Changes in biochemical markers after lower limb fractures. Stoffel, K., Engler, H., Kuster, M., Riesen, W. Clin. Chem. (2007) [Pubmed]
  21. Rat antigen-induced arthritis: cartilage alterations assessed with iodine-123-antileukoproteinase. Kinne, R.W., Meyer, P., Gründer, W., Buchner, E., Palombo-Kinne, E., Heinzel-Wieland, R., Becker, W., Wolf, F., Kalden, J.R., Burkhardt, H. J. Nucl. Med. (1998) [Pubmed]
  22. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. Sowa, H., Kaji, H., Yamaguchi, T., Sugimoto, T., Chihara, K. J. Bone Miner. Res. (2002) [Pubmed]
  23. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. Berneis, K., Rizzo, M., Lazzaroni, V., Fruzzetti, F., Carmina, E. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  24. Dominant strictures in patients with primary sclerosing cholangitis. Björnsson, E., Lindqvist-Ottosson, J., Asztely, M., Olsson, R. Am. J. Gastroenterol. (2004) [Pubmed]
  25. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Anber, V., Griffin, B.A., McConnell, M., Packard, C.J., Shepherd, J. Atherosclerosis (1996) [Pubmed]
  26. Vitamin A up-regulates expression of bone-type alkaline phosphatase in rat small intestinal crypt cell line and fetal rat small intestine. Nikawa, T., Rokutan, K., Nanba, K., Tokuoka, K., Teshima, S., Engle, M.J., Alpers, D.H., Kishi, K. J. Nutr. (1998) [Pubmed]
  27. Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Wilkinson, P., Leach, C., Ah-Sing, E.E., Hussain, N., Miller, G.J., Millward, D.J., Griffin, B.A. Atherosclerosis (2005) [Pubmed]
  28. Enrichment of osteogenic cell populations from rat bone marrow stroma. van den Dolder, J., Jansen, J.A. Biomaterials (2007) [Pubmed]
WikiGenes - Universities